Biofrontera (NASDAQ:BFRI) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Biofrontera (NASDAQ:BFRI) from a buy rating to a hold rating in a report released on Sunday morning,Wall Street Zen reports.

BFRI has been the subject of a number of other reports. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Zacks Research raised Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Biofrontera has an average rating of “Hold”.

Biofrontera Price Performance

Biofrontera stock opened at $1.32 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. The company’s 50-day moving average is $1.31 and its 200-day moving average is $1.08. The firm has a market capitalization of $19.60 million, a PE ratio of -2.93 and a beta of 0.83. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.66.

Biofrontera (NASDAQ:BFRI) last issued its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. Sell-side analysts anticipate that Biofrontera will post -0.6 earnings per share for the current year.

About Biofrontera

Biofrontera Inc (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business.